Status: Not yet recruiting
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Changhai HospitalUpdated: Mar 24, 2026
Eligibility criteria
Gender: no restriction; Age: 18-75 years. [+12]
Known history of hypersensitivity to macromolecular protein preparations. Contra... [+15]